These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34940791)

  • 1. Decreasing drug waste, reducing drug costs, and improving workflow efficiency through the implementation of automated chemotherapy dose rounding rules in the electronic health record system.
    Shah V; Spence A; Bartels T; Betcher J; Soefje S
    Am J Health Syst Pharm; 2022 Apr; 79(8):676-682. PubMed ID: 34940791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial Impact of an Automated Oncology Dose-Rounding Initiative: One-Year Analysis.
    Dela-Pena JC; Eschenburg KA; LaRocca VW; Patel D; Hough SM
    JCO Clin Cancer Inform; 2021 Aug; 5():805-810. PubMed ID: 34351786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated parenteral chemotherapy dose-banding to improve patient safety and decrease drug costs.
    Fahey OG; Koth SM; Bergsbaken JJ; Jones HA; Trapskin PJ
    J Oncol Pharm Pract; 2020 Mar; 26(2):345-350. PubMed ID: 31046608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the potential impact of dose rounding parenteral chemotherapy agents on cost savings and drug waste minimization.
    Chillari KA; Southward J; Harrigan N
    J Oncol Pharm Pract; 2018 Oct; 24(7):507-510. PubMed ID: 28732452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
    Copur MS; Gnewuch C; Schriner M; Tharnish M; Gonen M; McDonald M; Kezeor J; Ramaekers RC; Gauchan D; Clark D; Greenwalt L; Mickey M; Norvell M
    J Oncol Pharm Pract; 2018 Mar; 24(2):116-120. PubMed ID: 29284380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
    Francis SM; Heyliger A; Miyares MA; Viera M
    J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding.
    Lindsey S; Parsons LB; Figg LR; Rhodes J
    J Oncol Pharm Pract; 2018 Jan; 24(1):47-55. PubMed ID: 29251257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost savings from dose rounding of biologic anticancer agents in adults.
    Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
    J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution.
    Graff JM; Cramer J; Kolb LL; Agherrabi Z; Burgess M
    J Oncol Pharm Pract; 2024 Jun; 30(4):705-709. PubMed ID: 37350075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.
    Vandyke TH; Athmann PW; Ballmer CM; Kintzel PE
    J Oncol Pharm Pract; 2017 Jul; 23(5):379-383. PubMed ID: 27000279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rounding rituximab dose to nearest vial size.
    Patel S; Le A
    J Oncol Pharm Pract; 2013 Sep; 19(3):218-21. PubMed ID: 23114093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cost savings of biosimilar and dose rounding utilization in oncology care.
    Abdelmeseh V; Brown BR; Huynh JP; Zullo AR
    J Oncol Pharm Pract; 2023 Sep; 29(6):1437-1442. PubMed ID: 36259235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology.
    El Baraka S; Cherif Chefchaouni A; Bourdaime A; Ouedraogo JM; Shytry O; Belahcen MJ; Rahali Y
    J Oncol Pharm Pract; 2023 Sep; ():10781552231203403. PubMed ID: 37728162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center.
    Moore DC; McVey GN
    J Oncol Pharm Pract; 2018 Jan; 24(1):42-46. PubMed ID: 27760811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings.
    Jarkowski A; Nestico JS; Vona KL; Khushalani NI
    J Oncol Pharm Pract; 2014 Feb; 20(1):47-50. PubMed ID: 23512270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of dose rounding of chemotherapy to the nearest vial size.
    Dooley MJ; Singh S; Michael M
    Support Care Cancer; 2004 Sep; 12(9):653-6. PubMed ID: 14986078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions to reduce waste and improve billing compliance with medications in single-dose vials.
    Trovato A; Tyler LS; Nickman NA; Findlay R
    Am J Health Syst Pharm; 2023 Feb; 80(4):222-226. PubMed ID: 36322482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study.
    Yu JK; Iorio A; Chelle P; Edginton AN
    Haemophilia; 2021 May; 27(3):358-365. PubMed ID: 33650745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association.
    Fahrenbruch R; Kintzel P; Bott AM; Gilmore S; Markham R
    J Oncol Pract; 2018 Mar; 14(3):e130-e136. PubMed ID: 29400987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.
    Hess LM; Cui ZL; Li XI; Oton AB; Shortenhaus S; Watson IA
    J Med Econ; 2018 Aug; 21(8):755-761. PubMed ID: 29673274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.